Drug Profile
Lulizumab pegol - Bristol-Myers Squibb
Alternative Names: BMS-931699; LulizumabLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Monoclonal antibodies; Polyethylene glycols
- Mechanism of Action CD28 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Renal transplant rejection
- Discontinued Sjogren's syndrome; Systemic lupus erythematosus
Most Recent Events
- 14 Sep 2023 Bristol-Myers Squibb and National Institute of Allergy and Infectious Diseases completes the phase-I/II CTOT-24 trial in Renal transplant rejection (Combination therapy, In adults, In the elderly) in USA (SC) (NCT04066114)
- 22 Sep 2022 Bristol-Myers Squibb withdraws phase II trial in Renal transplant recipients and Kidney transplantation in US due to limited period of availability of a supply of the study drug and difficulties in enrollment in USA (NCT04903054)
- 12 Apr 2021 Discontinued - Phase-II for Sjogren's syndrome in South Africa, Russia, Puerto Rico, Poland, Peru, Mexico, Italy, Chile, Australia, USA (SC) before April 2021 (Bristol-Myers Squibb website, April 2021)